Abstract
While classical neuroleptics are characterized by dopamine D2 antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action of these new atypical antipsychotics can be classified into three general groups: a) binding to D2 together with non-dopaminergic receptors, b) interaction with dopamine receptor subtypes other than D2 and c) selective binding to nondopaminergic systems, such as glutamatergic, sigma, neurotensin, and cannabinoid.
Keywords: Antipsychotic Drugs, D2 antagonism, dopamine receptor, neurotensin, glutamatergic, nondopaminergic
Mini-Reviews in Medicinal Chemistry
Title: Current Strategies for the Development of Novel Antipsychotic Drugs
Volume: 3 Issue: 3
Author(s): Jordi Bolos
Affiliation:
Keywords: Antipsychotic Drugs, D2 antagonism, dopamine receptor, neurotensin, glutamatergic, nondopaminergic
Abstract: While classical neuroleptics are characterized by dopamine D2 antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action of these new atypical antipsychotics can be classified into three general groups: a) binding to D2 together with non-dopaminergic receptors, b) interaction with dopamine receptor subtypes other than D2 and c) selective binding to nondopaminergic systems, such as glutamatergic, sigma, neurotensin, and cannabinoid.
Export Options
About this article
Cite this article as:
Bolos Jordi, Current Strategies for the Development of Novel Antipsychotic Drugs, Mini-Reviews in Medicinal Chemistry 2003; 3 (3) . https://dx.doi.org/10.2174/1389557033488169
DOI https://dx.doi.org/10.2174/1389557033488169 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Motor Complications in Parkinson’s Disease: A Comprehensive Review of Emergent Management Strategies
CNS & Neurological Disorders - Drug Targets Neuropeptidomics: Improvements in Mass Spectrometry Imaging Analysis and Recent Advancements
Current Protein & Peptide Science New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Subject Index to Volume 4
Current Topics in Medicinal Chemistry Molecular Biomarkers in Schizophrenia – Implications for Clinical Practice
Current Psychiatry Reviews Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology Comparison of Mono-dopaminergic and Multi-target Pharmacotherapies in Primary Parkinson Syndrome and Assessment Tools to Evaluate Motor and Non-motor Symptoms
Current Drug Therapy Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Half a Century of l-DOPA
Current Topics in Medicinal Chemistry Adenosine, Ketogenic Diet and Epilepsy: The Emerging Therapeutic Relationship Between Metabolism and Brain Activity
Current Neuropharmacology New Insights on Dimethylaminoethanol (DMAE) Features as a Free Radical Scavenger
Drug Metabolism Letters Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling
Current Medicinal Chemistry - Central Nervous System Agents Neuropsychological Aspects of Dual Diagnosis
Current Drug Abuse Reviews Recent Advances on Horizontal Lower Limb Rehabilitation Robot
Recent Patents on Mechanical Engineering Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Possible Neuroprotective Strategies for Huntingtons Disease
Current Neuropharmacology